Provided by Tiger Trade Technology Pte. Ltd.

SIHUAN PHARM

0.720
-0.010-1.37%
Volume:10.42M
Turnover:7.35M
Market Cap:6.56B
PE:36.55
High:0.725
Open:0.720
Low:0.685
Close:0.730
52wk High:1.896
52wk Low:0.685
Shares:9.12B
HK Float Shares:9.12B
Volume Ratio:0.49
T/O Rate:0.11%
Dividend:0.01
Dividend Rate:1.56%
EPS(LYR):0.020
ROE:5.57%
ROA:2.80%
PB:0.91
PE(LYR):36.55
PS:2.13

Loading ...

四环医药控股集团2025年业绩回顾:营收同比增长37.7%,成功实现扭亏为盈

Bulletin Express
·
Apr 27

SIHUAN PHARM Publishes FY2025 Annual Report and ESG Report

Bulletin Express
·
Apr 27

SIHUAN PHARM (00460) Trustee Acquires 3 Million Shares Under Incentive Scheme

Stock News
·
Apr 21

Sihuan Pharmaceutical share award scheme trustee buys 3,000,000 shares at HK$1.36 average

Reuters
·
Apr 21

SIHUAN PHARM Shares Climb Nearly 3% as Subsidiary XUANZHUBIO-B Presents Promising Data on Diraoc in First-Line NSCLC Treatment at AACR

Stock News
·
Apr 21

Xuanzhu says Phase 1b NG-350A plus chemoradiotherapy hits 50% composite response rate

Reuters
·
Apr 20

Sihuan Pharma - Dirozalkib Shows Significant Efficacy Advantages in First-Line Alk-Positive Advanced Nsclc

THOMSON REUTERS
·
Apr 20

Sihuan Pharma - Xuanzhu Biopharm Presents Phase Iii Dirozalkib Data for Alk-Positive Nsclc at 2026 Aacr

THOMSON REUTERS
·
Apr 20

Xuanzhu says Phase III trial shows dirozalkib cuts lung cancer progression risk 53%

Reuters
·
Apr 19

Xuanzhu Biopharma wins HKEX approval to list 357,245,794 converted H shares

Reuters
·
Apr 17

Sihuan Pharm’s Xuanzhu Biopharm Secures CDE Approval for Phase III Trial of Anaprazole Sodium in Helicobacter Pylori Eradication

Bulletin Express
·
Apr 15

BUZZ-Xuanzhu Biopharmaceutical climbs to three-week high on approval for drug clinical trial

Reuters
·
Apr 15

Xuanzhu Biopharma wins China CDE nod for Phase III Anaprazole H. pylori trial

Reuters
·
Apr 15

BUZZ-China's Xuanzhu set for best day in 6 months on drug deal with Boston Oncology

Reuters
·
Apr 10

SIHUAN PHARM Subsidiary Xuanzhu Biopharm Inks >US$100 Million Licensing & Supply Deal with Boston Oncology for Breast and Lung Cancer Drugs in MENA

Bulletin Express
·
Apr 09

BRIEF-Xuanzhu Biopharmaceutical Enters Licensing Agreement With Boston Oncology

Reuters
·
Apr 09

Xuanzhu Biopharm licenses breast cancer, lung cancer drugs to Boston Oncology in MENA deal

Reuters
·
Apr 09